Induction of systemic TNFα in Natalizumab-treated multiple sclerosis
Induction of systemic TNFα in Natalizumab-treated multiple sclerosis
复制标题
DOI：
10.1111/j.1468-1331.2007.02037.x
复制
发表时间：
2008-03-01
影响因子：
5.1
通讯作者：
Wallstrom, E.
中科院分区：
文献类型：
--
作者：
Khademi, M.;Stol, D.;Wallstrom, E.
检测19例多发性硬化症患者外周血单核细胞中8种不同细胞因子的mRNA表达水平，分别在基线和那他珠单抗开放治疗6个月后进行。肿瘤坏死因子α的细胞表达和分泌肿瘤坏死因子α和干扰素γ蛋白的细胞数在6个月内显著增加。Kurtzke EDSS评分的提高是因为复发的解决，而不是疲劳严重程度评分。观察到的增加全身炎性细胞因子的那他珠单抗治疗与疲劳和系统免疫进行了讨论。
The mRNA expression of eight different cytokines in peripheral blood mononuclear cells in 19 individuals with multiple sclerosis was determined at baseline and after 6 months of open-label treatment with natalizumab. Cellular expression of tumor necrosis factor alpha (TNF alpha) mRNA and number of cells secreting TNF alpha and interferon gamma protein significantly increased over the 6 months. Kurtzke EDSS scores improved because of the resolution of relapses, but not fatigue severity scores. The observed increases in systemic proinflammatory cytokines by natalizumab treatment are discussed in relation to fatigue and systemic immunity.